Over the last 5 years, five clinical trials were published (three from the USA, one from Canada and one from France), which evaluated the PI3K targeted therapy in recurrent or metastatic HNSCC patients, heavily pre-treated HNSCC patients, or locoregionally advanced SCCHN (LA-SCCHN) patients. Here, PIK3CB is linked to head and neck squamous cell carcinoma.